This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
The revelation adds detail to a CISA advisory on Thursday that did not say that ...
Start of procedure - extension of marketing authorisation (26 April - 22 May 2025)
Start of procedure: Type II variation - extension of indication (26 April - 22 M...
Human medicines European public assessment report (EPAR): Sorafenib Accord, sora...
Human medicines European public assessment report (EPAR): HyQvia, human normal i...
Human medicines European public assessment report (EPAR): Inflectra, infliximab,...
Human medicines European public assessment report (EPAR): Ovaleap, follitropin a...
Human medicines European public assessment report (EPAR): Prevymis, letermovir, ...
Human medicines European public assessment report (EPAR): Zomarist, vildagliptin...
Human medicines European public assessment report (EPAR): Icandra (previously Vi...
Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,...
Human medicines European public assessment report (EPAR): Paxlovid, nirmatrelvir...
And more biotech news brought to you by The Readout.
Human medicines European public assessment report (EPAR): Xenpozyme, olipudase a...
Human medicines European public assessment report (EPAR): Galafold, migalastat, ...
The FDA has slapped a clinical hold on Rocket Pharmaceuticals’ pivotal gene ther...
Big Biotech Biogen is venturing into the city, paying $16 million in cash to par...
The FDA approved Abbott's Tendyne minimally invasive heart replacement for mitra...
The FDA has slapped Savara with a refuse to file letter after the biotech in Mar...
Almost all the patients with depression who received Gilgamesh Pharmaceuticals’ ...
With the goal to become a top 3 pharma company in China, Novartis has been busy ...
When you know you're a vehicle's final owner, why not glue stuff all over it? Du...
I was all but convinced that the new tariff situation would lead Toyota to cance...
Objectively good? Maybe not. Lovable all the same? Absolutely.